idarubicin has been researched along with T-Cell Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aleksyk, OM; Kryachok, IA | 1 |
| Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
3 other study(ies) available for idarubicin and T-Cell Lymphoma
| Article | Year |
|---|---|
[IMMUNOHISTOCHEMICAL FACTORS OF SMALL-CELL LYMPHOMAS AND CHOICE OF TREATMENT WTTH LEVEL INCLUSION].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Female; Gamma Rays; Gene Expression; Humans; Idarubicin; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Prednisolone; Prednisone; Protein Kinase C beta; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Tumor Suppressor Protein p53; Ukraine; Vincristine | 2014 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine | 1997 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |